亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies

阿替唑单抗 彭布罗利珠单抗 无容量 阿维鲁单抗 医学 肿瘤科 肺癌 内科学 危险系数 荟萃分析
作者
Maofen Jiang,Chunjiao Liu,Dongxiao Ding,Hui Tian,Chaoqun Yu
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:12
标识
DOI:10.3389/fonc.2022.827050
摘要

Objective The present network meta-analysis (NMA) was conducted to summarize the direct and indirect evidence of common programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors including avelumab, atezolizumab, cemiplimab, nivolumab, and pembrolizumab for the treatment of non-small cell lung cancer (NSCLC) patients and further to determine the optimal therapeutic regimen. Methods We performed a systematic literature search to identify all potentially eligible studies in PubMed, Embase, and the Cochrane Library until August 7, 2021. The primary outcome was overall survival (OS), and the second outcome was treatment-related adverse events (TRAEs). We used random-effects model to conduct direct and network meta-analyses, which were performed by using RevMan 5.3 and R version 3.6.1, respectively. Results Direct meta-analysis suggested that atezolizumab, cemiplimab, nivolumab, or pembrolizumab significantly improved OS compared with chemotherapy (CT), and NMA further established that atezolizumab [hazard ratio (HR), 0.77; 95% CrI, 0.62–0.96], nivolumab (HR, 0.75; 95% CrI, 0.62–0.93), or pembrolizumab (HR, 0.71; 95% Credible interval (Crl), 0.57–0.89) significantly and cemiplimab (HR, 0.68; 95% CrI, 0.46–1.02) numerically improved OS compared with CT. Meanwhile, NMA also indicated that cemiplimab was numerically superior to other PD-1/PD-L1 agents. Moreover, avelumab, atezolizumab, cemiplimab, nivolumab, and pembrolizumab were found to have fewer TRAEs compared with CT in direct meta-analysis, which were supported by the results from the NMA. Meanwhile, surface under the cumulative ranking curve (SUCRA) and ranking probability suggested that cemiplimab provided the most favorable balance between efficacy and safety, with the first ranking for the OS. Conclusions Based on available evidence, cemiplimab may have the most favorable risk–benefit ratio for NSCLC patients compared with other common therapeutic management. However, future research with a large-scale, high-quality, and mature follow-up is needed to further determine which agents should be preferentially selected for NSCLC patients due to the limitations of our NMA and variations of eligible studies in treatment line and PD-L1 status.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hello的应助被soilman采纳,获得10
5秒前
尊敬怀柔完成签到 ,获得积分10
6秒前
隐形曼青的应助被April采纳,获得10
10秒前
有魅力初夏完成签到,获得积分10
11秒前
怡然晓兰完成签到 ,获得积分10
14秒前
16秒前
旺仔仔完成签到,获得积分10
16秒前
兮陌完成签到 ,获得积分10
22秒前
April发布了新的文献求助10
22秒前
玲玲完成签到,获得积分10
23秒前
危机的觅风完成签到,获得积分10
24秒前
26秒前
soilman发布了新的文献求助10
29秒前
flora完成签到 ,获得积分10
34秒前
优秀函完成签到,获得积分10
46秒前
小巧慕儿完成签到,获得积分10
47秒前
54秒前
54秒前
claire完成签到 ,获得积分10
54秒前
平常香发布了新的文献求助10
57秒前
玲玲发布了新的文献求助10
59秒前
meng完成签到 ,获得积分10
1分钟前
1分钟前
Maestro_S的应助被平常香采纳,获得10
1分钟前
仰勒完成签到 ,获得积分10
1分钟前
科目三的应助被Lonely采纳,获得10
1分钟前
leo123发布了新的文献求助10
1分钟前
美满的夏山完成签到 ,获得积分10
1分钟前
SciGPT的应助被soilman采纳,获得10
1分钟前
复杂的雁芙完成签到,获得积分10
1分钟前
1分钟前
1分钟前
soilman发布了新的文献求助10
1分钟前
时之王者发布了新的文献求助10
1分钟前
TwentyNine完成签到 ,获得积分10
1分钟前
是小妤呀完成签到 ,获得积分10
1分钟前
贪玩的夏真完成签到,获得积分10
1分钟前
青云完成签到,获得积分10
1分钟前
1分钟前
独特的紫雪完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185091
求助须知:如何正确求助?哪些是违规求助? 9574009
关于积分的说明 21833941
捐赠科研通 7782532
什么是DOI,文献DOI怎么找? 3434500
关于科研通互助平台的介绍 2558701
邀请新用户注册赠送积分活动 2481201